Sidney Kimmel Comprehensive Cancer Center retweeted
During #AACRdisp26, Joseph P. Flemming, DO, of @JeffHealthAb shared how the Same Day/Next Day program is helping at-risk patients with cancer overcome barriers to care and receive first-list treatment. brnw.ch/21x6xW3
3
2
5
789
Sidney Kimmel Comprehensive Cancer Center retweeted
The Same Day/Next Day program is a rapid referral program designed to identify and help at-risk patients with cancer to overcome barriers in cancer care
Great work by my colleague Joseph P. Flemming, DO, presented at #AACRdisp26
@KimmelCancerCtr
@AvnishBhatiaMD @TJUHospital
Great work by my colleague Joseph P. Flemming, DO, presented at #AACRdisp26
@KimmelCancerCtr
@AvnishBhatiaMD @TJUHospital
A rapid clinical care program increased access for vulnerable patients, and a higher proportion of them initiated first-line therapy than through the traditional healthcare path, according to research reported at #AACRdisp26. Learn more: brnw.ch/21x6ytc @JeffHealthAb
0
1
1
164
Sidney Kimmel Comprehensive Cancer Center retweeted
A rapid clinical care program increased access for vulnerable patients, and a higher proportion of them initiated first-line therapy than through the traditional healthcare path, according to research reported at #AACRdisp26. Learn more: brnw.ch/21x6ytc @JeffHealthAb
0
2
5
1,039
Sidney Kimmel Comprehensive Cancer Center retweeted
A very Philadelphia General Session at our Fall 2026 Group Meeting. Delighted to be joined by @AACR_CEO of @AACR and Cancer Center Directors Dr. Vonderheide of @PennCancer, Dr. Chapman of @KimmelCancerCtr & @DrRobWinn of @FoxChaseCancer! #CancerResearch
0
2
4
624
Sidney Kimmel Comprehensive Cancer Center retweeted
How do you approach a T3N0 laryngeal cancer with erosion of the thyroid cartilage?
This week’s Case Highlight features Drs. Dylan Roden, Ravindra Uppaluri (@DrUppaluri), and Adam Luginbuhl discussing treatment considerations for an anterior laryngeal cancer with thyroid cartilage involvement.
Explore this case and more clinical discussions in the BackTable App: backtable.com/shows/ent/case…
#ENT #HeadAndNeckCancer #LaryngealCancer #Oncology @KimmelCancerCtr @Jefferson_OTO @hncalliance @gopibshah
This week’s Case Highlight features Drs. Dylan Roden, Ravindra Uppaluri (@DrUppaluri), and Adam Luginbuhl discussing treatment considerations for an anterior laryngeal cancer with thyroid cartilage involvement.
Explore this case and more clinical discussions in the BackTable App: backtable.com/shows/ent/case…
#ENT #HeadAndNeckCancer #LaryngealCancer #Oncology @KimmelCancerCtr @Jefferson_OTO @hncalliance @gopibshah
0
7
10
556
Sidney Kimmel Comprehensive Cancer Center retweeted
What's next in melanoma research and treatment? Hear from experts, connect with the community and discover resources at the Together Against Melanoma Patient and Caregiver Symposium Sept. 26 held in partnership with @KimmelCancerCtr @UMBC Register today: · buff.ly/8tE8yx1
1
1
2
271
Sidney Kimmel Comprehensive Cancer Center retweeted
🚹 Nearly 40% of men with #ProstateCancer had newly documented metabolic syndrome within 12 months of starting ADT + ARPI.
➡️ Highlights the importance of early metabolic monitoring
🔹Drs. Amy L. Shaver & Grace Lu-Yao of @KimmelCancerCtr | @JAMAOnc
🔗 ascopost.com/news/august-20…
➡️ Highlights the importance of early metabolic monitoring
🔹Drs. Amy L. Shaver & Grace Lu-Yao of @KimmelCancerCtr | @JAMAOnc
🔗 ascopost.com/news/august-20…
1
2
3
1,485
Sidney Kimmel Comprehensive Cancer Center retweeted
New in the #RedJournal: New LIME trial results with @DrLydiaJWilson et al. 4DCT‑ventilation–based predictions of postop lung function showed strong concordance with measured PFTs (CCC 88–91%), meeting the primary endpoint. @KimmelCancerCtr tinyurl.com/rjlime
1
4
17
1,736
Sidney Kimmel Comprehensive Cancer Center retweeted
Register for the Uveal Melanoma Patient & Caregiver Educational Symposium on Sept 19! Learn from leading experts, connect with the OM community and hear the latest research updates. @KimmelCancerCtr
Register by September 4: skccext.jefferson.edu/events/2026_,M…
Register by September 4: skccext.jefferson.edu/events/2026_,M…
0
2
2
127
Sidney Kimmel Comprehensive Cancer Center retweeted
💡The #Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant #Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical #Trials
✍️by Amy L. Shaver, Nikita Nikita et al. @KimmelCancerCtr
Unlock🔓mdpi.com/2072-6694/17/1…
✍️by Amy L. Shaver, Nikita Nikita et al. @KimmelCancerCtr
Unlock🔓mdpi.com/2072-6694/17/1…
0
1
1
233
Sidney Kimmel Comprehensive Cancer Center retweeted
Congratulations to Drs. Ridhdhi Desai and Richard Zheng on receiving a $200k grant from The Concern Foundation for #PancreaticCancer research – a collaboration between @KimmelCancerCtr @JeffersonUniv and @DrexelBiochem @DrexelUniv
@ridhdhidesai @RZheng8 @Danglab1 @ConcernFdn👏
@ridhdhidesai @RZheng8 @Danglab1 @ConcernFdn👏
1
4
10
1,480
Sidney Kimmel Comprehensive Cancer Center retweeted
Earlier today, Dr. Margie Kasner (@KimmelCancerCtr) and AACI President Dr. Joann B. Sweasy (@BuffettCancer) welcomed nearly 600 attendees to #CRI2026 with remarks on maximizing the #AACICRI meeting experience and prioritizing access to clinical trials for all patients.
0
2
1
296
Sidney Kimmel Comprehensive Cancer Center retweeted
Uveal beyond tebentafusp. OptimUM-02 (daro+crizo vs IC, 1L HLA-A2-neg): PFS 6.9 vs 3.1 mo (HR 0.42), ORR 37.1% vs 5.8%. Marlana Orloff @KimmelCancerCtr
Potential new standard where none existed. Uveal TIL (n=32) ORR 22%, only in tumor-reactive products (UMIS 44% vs 8%).
Potential new standard where none existed. Uveal TIL (n=32) ORR 22%, only in tumor-reactive products (UMIS 44% vs 8%).
1
1
1
194
Sidney Kimmel Comprehensive Cancer Center retweeted
Had a great time speaking with Ariana Neely, MD, of
Jefferson Einstein Philadelphia Hospital, who shared findings from a real-world analysis of GLP-1 receptor agonist use and lung cancer incidence in high-risk patients @ASCO #ASCO26 #lcsm #oncology
Jefferson Einstein Philadelphia Hospital, who shared findings from a real-world analysis of GLP-1 receptor agonist use and lung cancer incidence in high-risk patients @ASCO #ASCO26 #lcsm #oncology
0
2
4
516
Sidney Kimmel Comprehensive Cancer Center retweeted
Caught up with Dr. Marcus Butler and Dr. Rino Seedor @RSeedor in front of our neoadjuvant uveal melanoma trials-in-progress posters in support of Eye on Grace #eyepatchchallenge #asco26 #endmelanoma #uvealmelanoma
0
2
5
333
Sidney Kimmel Comprehensive Cancer Center retweeted
Same Day Next Day Cancer Program of @KimmelCancerCtr presented at #ASCO26
Rapid referral programs are set to improve cancer care & more to come!
Thanks @ConquerCancerFd for Merit Award
Thanks @AvnishBhatiaMD for leading this project!
@ASCO
#qualityimprovement
Rapid referral programs are set to improve cancer care & more to come!
Thanks @ConquerCancerFd for Merit Award
Thanks @AvnishBhatiaMD for leading this project!
@ASCO
#qualityimprovement
1
1
10
835
Sidney Kimmel Comprehensive Cancer Center retweeted
Honoured to receive a Young Investigator Award from @ConquerCancerFd @ASCO
Thank you to my amazing mentors @DrZarour @diwakardavar & colleagues @UPMCHillmanCC and @KimmelCancerCtr all those who helped me along the way
Thank you to my amazing mentors @DrZarour @diwakardavar & colleagues @UPMCHillmanCC and @KimmelCancerCtr all those who helped me along the way
We're thrilled to officially announce the 2026 class of Conquer Cancer Grants and Awards recipients! 🔬 These grants empower the next generation of physician-scientists to turn innovative ideas into clinical breakthroughs. Congratulations to the new class—see you in Chicago for recipients here: bit.ly/4x0qpBF
#ResearchConquersCancer #ConquerCancer @ASCO
3
1
21
2,321
Sidney Kimmel Comprehensive Cancer Center retweeted
Caught up w/ Dr Matteo Carlino after presenting sustained 5yr benefit w/ adj mRNA-4157/pembro vs pembro in cutaneous mel & Dr Marlana Orloff after *practice-changing* daro/criz in pts w/ uveal melanoma 👏🏼
#eyepatchchallenge #asco26 @LutzkyJose @SCRIOncology @KimmelCancerCtr
#eyepatchchallenge #asco26 @LutzkyJose @SCRIOncology @KimmelCancerCtr
1
1
7
357
Dr. Marlana Orloff presented results from the OptimUM-02 trial of darovasertib + crizotinib in metastatic uveal melanoma
at #ASCO26 ➡️ asco.org/abstracts-pres…
at #ASCO26 ➡️ asco.org/abstracts-pres…
0
1
3
240
Novel approach to alleviate morbidity of subsequent surgical resection in patients with basal cell carcinoma of the head and neck: Safety and efficacy data from a phase II trial of neoadjuvant cemiplimab #ASCO26
➡️ asco.org/abstracts-pres…
➡️ asco.org/abstracts-pres…
0
0
2
151









































